{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:16:50Z","timestamp":1791238610235,"version":"4.1.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jilin Province Science and Technology Development Program Project","award":["YDZJ202501ZYTS183"],"award-info":[{"award-number":["YDZJ202501ZYTS183"]}]},{"name":"the Project of Lung Cancer Targeted Therapy Research of Beijing CSCO","award":["No. Y-2021AST\/qn-0013"],"award-info":[{"award-number":["No. Y-2021AST\/qn-0013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s43440-025-00700-1","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T11:44:56Z","timestamp":1738583096000},"page":"392-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Off-label use of anlotinib in malignancies\u2019 treatment: efficacy and management of adverse reactions"],"prefix":"10.1007","volume":"77","author":[{"given":"Guangli","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-383X","authenticated-orcid":false,"given":"Xiaodan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"issue":"15","key":"700_CR1","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2012.46.8934","volume":"31","author":"LA Garraway","year":"2013","unstructured":"Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013;31(15):1806\u201314.","journal-title":"J Clin Oncol"},{"issue":"1","key":"700_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-020-00858-6","volume":"13","author":"Q Luo","year":"2020","unstructured":"Luo Q, Wang J, Zhao W, Peng Z, Liu X, Li B, et al. Vasculogenic mimicry in carcinogenesis and clinical applications. J Hematol Oncol. 2020;13(1):19.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"700_CR3","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1158\/0008-5472.CAN-16-0675","volume":"76","author":"RG Bagley","year":"2016","unstructured":"Bagley RG. Commentary on Folkman: \u201ctumor angiogenesis factor.\u201d Cancer Res. 2016;76(7):1673\u20134.","journal-title":"Cancer Res"},{"key":"700_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3389\/fonc.2020.00664","volume":"10","author":"J Ma","year":"2020","unstructured":"Ma J, Song Y, Shou J, Bai Y, Li H, Xie X, et al. Anlotinib for patients with metastatic renal cell carcinoma previously treated with one vascular endothelial growth factor receptor-tyrosine kinase inhibitor: a phase 2 trial. Front Oncol. 2020;10:664.","journal-title":"Front Oncol"},{"issue":"4","key":"700_CR5","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.21037\/tlcr-21-192","volume":"10","author":"T Li","year":"2021","unstructured":"Li T, Qian Y, Zhang C, Uchino J, Provencio M, Wang Y, et al. Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo. Transl Lung Cancer Res. 2021;10(4):1873\u201388.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"700_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12885-023-11776-4","volume":"24","author":"S Zhao","year":"2024","unstructured":"Zhao S, Zhang M, Zhang Q, Wu J, Dai H. Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial. BMC Cancer. 2024;24(1):6.","journal-title":"BMC Cancer"},{"issue":"3","key":"700_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/jcpt.12507","volume":"42","author":"MM Saiyed","year":"2017","unstructured":"Saiyed MM, Ong PS, Chew L. Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Ther. 2017;42(3):251\u20138.","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"700_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00128072-200204060-00002","volume":"4","author":"S Conroy","year":"2002","unstructured":"Conroy S. Unlicensed and off-label drug use: issues and recommendations. Paediatr Drugs. 2002;4(6):353\u20139.","journal-title":"Paediatr Drugs"},{"key":"700_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","volume":"654","author":"B Lin","year":"2018","unstructured":"Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1. Gene. 2018;654:77\u201386.","journal-title":"Gene"},{"key":"700_CR10","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.2147\/DDDT.S426898","volume":"17","author":"S Li","year":"2023","unstructured":"Li S, Wang H. Research progress on mechanism and management of adverse drug reactions of anlotinib. Drug Des Devel Ther. 2023;17:3429\u201337.","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"700_CR11","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s00262-020-02641-5","volume":"69","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li L, Jiang Z, Wang B, Pan Z. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunol Immunother. 2020;69(12):2523\u201332.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"700_CR12","doi-asserted-by":"publisher","first-page":"2120676","DOI":"10.1080\/2162402X.2022.2120676","volume":"11","author":"R Barnestein","year":"2022","unstructured":"Barnestein R, Galland L, Kalfeist L, Ghiringhelli F, Ladoire S, Limagne E. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. Oncoimmunology. 2022;11(1):2120676.","journal-title":"Oncoimmunology"},{"issue":"11","key":"700_CR13","doi-asserted-by":"publisher","first-page":"2300141","DOI":"10.1002\/adtp.202300141","volume":"6","author":"B Zou","year":"2023","unstructured":"Zou B, Jiang H, Liu H, Lu J, Qiang H, Lu M, et al. Anlotinib combined with anti-PD1 potentiates anti-tumor immunity via immunogenic cell death and macrophage reprogramming. Adv Ther. 2023;6(11):2300141.","journal-title":"Adv Ther"},{"issue":"2","key":"700_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3892\/ol.2020.11685","volume":"20","author":"Y Gao","year":"2020","unstructured":"Gao Y, Liu P, Shi R. Anlotinib as a molecular targeted therapy for tumors. Oncol Lett. 2020;20(2):1001\u201314.","journal-title":"Oncol Lett"},{"issue":"6","key":"700_CR15","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/aps.2017.199","volume":"39","author":"CC Zhong","year":"2018","unstructured":"Zhong CC, Chen F, Yang JL, Jia WW, Li L, Cheng C, et al. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species. Acta Pharmacol Sin. 2018;39(6):1048\u201363.","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"700_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/1759-7714.12977","volume":"10","author":"X Si","year":"2019","unstructured":"Si X, Zhang L, Wang H, Zhang X, Wang M, Han B, et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: experiences in ALTER-0303. Thorac Cancer. 2019;10(3):551\u20136.","journal-title":"Thorac Cancer"},{"issue":"1","key":"700_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","volume":"9","author":"Y Sun","year":"2016","unstructured":"Sun Y, Niu W, Du F, Du C, Li S, Wang J, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"700_CR18","doi-asserted-by":"publisher","first-page":"e702","DOI":"10.1634\/theoncologist.2018-0839","volume":"24","author":"AP Zhou","year":"2019","unstructured":"Zhou AP, Bai Y, Song Y, Luo H, Ren XB, Wang X, et al. Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial. Oncologist. 2019;24(8):e702\u20138.","journal-title":"Oncologist"},{"issue":"9","key":"700_CR19","first-page":"765","volume":"42","author":"Y Song","year":"2020","unstructured":"Song Y, Yihebali C, Yang L, Cui CX, Zhang W, Sun YK, et al. Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma. Zhonghua Zhong Liu Za Zhi. 2020;42(9):765\u201370.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"700_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.824607","volume":"13","author":"P Du","year":"2022","unstructured":"Du P, Xuan L, Hu T, An Z, Liu L. Serum eicosanoids metabolomics profile in a mouse model of renal cell carcinoma: predicting the antitumor efficacy of anlotinib. Front Immunol. 2022;13: 824607.","journal-title":"Front Immunol"},{"issue":"2","key":"700_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281402","volume":"18","author":"J Lin","year":"2023","unstructured":"Lin J, Fang Q, Zheng X. Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China. PLoS ONE. 2023;18(2): e0281402.","journal-title":"PLoS ONE"},{"issue":"1","key":"700_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2022.113197","volume":"417","author":"J Li","year":"2022","unstructured":"Li J, Cao P, Chen Y, Wang J, Sun X, Chen R, et al. Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment. Exp Cell Res. 2022;417(1): 113197.","journal-title":"Exp Cell Res"},{"issue":"40","key":"700_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017164","volume":"98","author":"Y Tang","year":"2019","unstructured":"Tang Y, Ou Z, Yao Z, Qiao G. A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma. Medicine. 2019;98(40): e17164.","journal-title":"Medicine"},{"issue":"5","key":"700_CR24","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/cam4.3771","volume":"10","author":"J Huang","year":"2021","unstructured":"Huang J, Xiao J, Fang W, Lu P, Fan Q, Shu Y, et al. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: a double-blind randomized phase 2 trial. Cancer Med. 2021;10(5):1681\u20139.","journal-title":"Cancer Med"},{"issue":"2","key":"700_CR25","first-page":"250","volume":"41","author":"W Sun","year":"2021","unstructured":"Sun W, Zou X, Zhang W, Hu S, Ge K. Clinical efficacy of anlotinib plus S-1 as a second-line therapy for recurrent or metastatic esophageal squamous cell carcinoma. J South Med Univ. 2021;41(2):250\u20135.","journal-title":"J South Med Univ"},{"issue":"1","key":"700_CR26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12916-022-02649-x","volume":"20","author":"N Li","year":"2022","unstructured":"Li N, Wu T, Hong YG, Guo YZ, Cheng YF, Ma YJ, et al. A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent\/advanced esophageal squamous cell carcinoma. BMC Med. 2022;20(1):472.","journal-title":"BMC Med"},{"key":"700_CR27","doi-asserted-by":"publisher","first-page":"153303382210809","DOI":"10.1177\/15330338221080939","volume":"21","author":"G Wang","year":"2022","unstructured":"Wang G, Beeraka NM, Xiao W, Zhang Y, Xue N, Chen G, et al. Comparative clinical efficacy of \u2018concurrent chemoradiotherapy (CCRT) and anlotinib\u2019 than CCRT in patients with locally advanced ESCC. Technol Cancer Res Treat. 2022;21:15330338221080940.","journal-title":"Technol Cancer Res Treat"},{"key":"700_CR28","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.2147\/DDDT.S335870","volume":"15","author":"H Yang","year":"2021","unstructured":"Yang H, Sun S, Mei Z, Xiang Q, Yang C, Chen M, et al. A retrospective cohort study evaluates clinical value of anlotinib in persistent, metastatic, or recurrent cervical cancer after failure of first-line therapy. Drug Des Dev Ther. 2021;15:4665\u201374.","journal-title":"Drug Des Dev Ther"},{"issue":"7","key":"700_CR29","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/modpathol.2016.64","volume":"29","author":"AM Heeren","year":"2016","unstructured":"Heeren AM, Punt S, Bleeker MC, Gaarenstroom KN, van der Velden J, Kenter GG, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol. 2016;29(7):753\u201363.","journal-title":"Mod Pathol"},{"issue":"16","key":"700_CR30","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.21.02091","volume":"40","author":"Q Xu","year":"2022","unstructured":"Xu Q, Wang J, Sun Y, Lin Y, Liu J, Zhuo Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial. J Clin Oncol. 2022;40(16):1795\u2013805.","journal-title":"J Clin Oncol"},{"issue":"12","key":"700_CR31","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2217\/imt-2023-0020","volume":"15","author":"G Niu","year":"2023","unstructured":"Niu G, Wang H, Ren Y, Xing X, Zhao L, Liu N, et al. Penpulimab and anlotinib in an elderly patient with recurrent cervical cancer: a case report and literature review. Immunotherapy. 2023;15(12):905\u201312.","journal-title":"Immunotherapy"},{"key":"700_CR32","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673276871231205043417","author":"S Zaib","year":"2024","unstructured":"Zaib S, Javed H, Rana N, Zaib Z, Iqbal S, Khan I. Therapeutic chemoresistance in ovarian cancer: emerging hallmarks, signaling mechanisms and alternative pathways. Curr Med Chem. 2024. https:\/\/doi.org\/10.2174\/0109298673276871231205043417.","journal-title":"Curr Med Chem"},{"issue":"1","key":"700_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23(1):66.","journal-title":"Mol Cancer"},{"issue":"20","key":"700_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020053","volume":"99","author":"L Sun","year":"2020","unstructured":"Sun L, Yang M, Zhang X, Li H, Wu L, Zhang Y, et al. Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: a case report. Medicine (Baltimore). 2020;99(20): e20053.","journal-title":"Medicine (Baltimore)"},{"key":"700_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/DDDT.S286529","volume":"15","author":"Q Cui","year":"2021","unstructured":"Cui Q, Hu Y, Ma D, Liu H. A retrospective observational study of anlotinib in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Drug Des Devel Ther. 2021;15:339\u201347.","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"700_CR36","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1136\/ijgc-2023-004777","volume":"33","author":"W Shen","year":"2023","unstructured":"Shen W, Jing C, Tian W, Zhang W, Ren Y, Shan B, et al. Anlotinib in patients with recurrent platinum resistant\/refractory ovarian cancer: a prospective, single arm, phase II study. Int J Gynecol Cancer. 2023;33(11):1764\u201370.","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"700_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100689","volume":"3","author":"CY Lan","year":"2022","unstructured":"Lan CY, Zhao J, Yang F, Xiong Y, Li R, Huang Y, et al. Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: a multi-center, single-arm, phase 1b trial. Cell Rep Med. 2022;3(7): 100689.","journal-title":"Cell Rep Med"},{"issue":"12","key":"700_CR38","doi-asserted-by":"publisher","first-page":"300060520976824","DOI":"10.1177\/0300060520976824","volume":"48","author":"P Zhang","year":"2020","unstructured":"Zhang P, Ma L, Wang X, Zhang R, Dong Y. Successful treatment of advanced ovarian cancer with anlotinib: a case report. J Int Med Res. 2020;48(12):300060520976824.","journal-title":"J Int Med Res"},{"issue":"12","key":"700_CR39","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.4161\/auto.22110","volume":"8","author":"Z Zou","year":"2012","unstructured":"Zou Z, Yuan Z, Zhang Q, Long Z, Chen J, Tang Z, et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy. 2012;8(12):1798\u2013810.","journal-title":"Autophagy"},{"key":"700_CR40","doi-asserted-by":"publisher","first-page":"960327123118577","DOI":"10.1177\/09603271231185774","volume":"42","author":"H Wang","year":"2023","unstructured":"Wang H, Wang Y. Anlotinib induces apoptosis and second growth\/mitosis phase block in cisplatin-resistant ovarian cancer cells via the aurora kinase A\/p53 pathway. Hum Exp Toxicol. 2023;42:9603271231185774.","journal-title":"Hum Exp Toxicol"},{"issue":"1","key":"700_CR41","first-page":"36","volume":"39","author":"M Zhou","year":"2019","unstructured":"Zhou M, Chen X, Zhang H, Xia L, Tong X, Zou L, et al. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun (Lond). 2019;39(1):36.","journal-title":"Cancer Commun (Lond)"},{"key":"700_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.810747","volume":"13","author":"Y Fu","year":"2022","unstructured":"Fu Y, Liu J, Jiang Y. Partial response after toripalimab plus anlotinib for advanced metaplastic breast carcinoma: a case report. Front Endocrinol. 2022;13: 810747.","journal-title":"Front Endocrinol"},{"issue":"1","key":"700_CR43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41392-023-01672-5","volume":"8","author":"Y Han","year":"2023","unstructured":"Han Y, Wang J, Sun T, Ouyang Q, Li J, Yuan J, et al. Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer. Signal Transduct Target Ther. 2023;8(1):429.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"700_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101563","volume":"8","author":"B Liu","year":"2023","unstructured":"Liu B, Liu L, Ran J, Xie N, Li J, Xiao H, et al. A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer. ESMO open. 2023;8(3): 101563.","journal-title":"ESMO open"},{"issue":"3","key":"700_CR45","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc3431","volume":"13","author":"M Xing","year":"2013","unstructured":"Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184\u201399.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"700_CR46","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621\u201330.","journal-title":"N Engl J Med"},{"issue":"9940","key":"700_CR47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319\u201328.","journal-title":"Lancet"},{"issue":"12","key":"700_CR48","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1089\/thy.2021.0307","volume":"31","author":"NS Huang","year":"2021","unstructured":"Huang NS, Wei WJ, Xiang J, Chen JY, Guan Q, Lu ZW, et al. The efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: a single-arm Phase II clinical trial. Thyroid. 2021;31(12):1808\u201313.","journal-title":"Thyroid"},{"issue":"3","key":"700_CR49","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s12020-023-03390-y","volume":"81","author":"X Zheng","year":"2023","unstructured":"Zheng X, Wang J, Ye T, Tang W, Pan X, Wang S, et al. Efficacy and safety of anlotinib-based chemotherapy for locally advanced or metastatic anaplastic thyroid carcinoma. Endocrine. 2023;81(3):540\u20136.","journal-title":"Endocrine"},{"issue":"5","key":"700_CR50","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.eprac.2024.02.005","volume":"30","author":"D Sun","year":"2024","unstructured":"Sun D, Zhang X, Sun Y, Mu Z, Wang H, Zhang Y, et al. Early structural, biochemical, and metabolic responses to anlotinib in patients with progressive radioactive iodine refractory differentiated thyroid cancer. Endocr Pract. 2024;30(5):456\u201364.","journal-title":"Endocr Pract"},{"issue":"1","key":"700_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1530\/ERC-17-0558","volume":"26","author":"X Ruan","year":"2019","unstructured":"Ruan X, Shi X, Dong Q, Yu Y, Hou X, Song X, et al. Antitumor effects of anlotinib in thyroid cancer. Endocr Relat Cancer. 2019;26(1):153\u201364.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"700_CR52","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41416-021-01340-x","volume":"125","author":"J Liang","year":"2021","unstructured":"Liang J, Jin Z, Kuang J, Feng H, Zhao Q, Yang Z, et al. The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis. Br J Cancer. 2021;125(3):390\u2013401.","journal-title":"Br J Cancer"},{"issue":"9","key":"700_CR53","doi-asserted-by":"publisher","first-page":"e230036","DOI":"10.1530\/ERC-23-0036","volume":"30","author":"J Wu","year":"2023","unstructured":"Wu J, Liang J, Liu R, Lv T, Fu K, Jiang L, et al. Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer. Endocr Relat Cancer. 2023;30(9):e230036.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"700_CR54","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/cancers5020591","volume":"5","author":"K Ando","year":"2013","unstructured":"Ando K, Heymann MF, Stresing V, Mori K, R\u00e9dini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel). 2013;5(2):591\u2013616.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"700_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/14737140.2018.1413939","volume":"18","author":"DJ Harrison","year":"2018","unstructured":"Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39\u201350.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"700_CR56","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/cells10010172","volume":"10","author":"A Smrke","year":"2021","unstructured":"Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH, Jones RL. Future directions in the treatment of osteosarcoma. Cells. 2021;10(1):172.","journal-title":"Cells"},{"issue":"21","key":"700_CR57","doi-asserted-by":"publisher","first-page":"7593","DOI":"10.1002\/cam4.4286","volume":"10","author":"Z Liu","year":"2021","unstructured":"Liu Z, Gao S, Zhu L, Wang J, Zhang P, Li P, et al. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: a retrospective multiple institution study. Cancer Med. 2021;10(21):7593\u2013600.","journal-title":"Cancer Med"},{"issue":"6","key":"700_CR58","doi-asserted-by":"publisher","first-page":"7073","DOI":"10.21037\/apm-20-1790","volume":"10","author":"ZY Long","year":"2021","unstructured":"Long ZY, Lu Y, Li M, Chen G, Shi L, Xiao X, et al. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review. Ann Palliat Med. 2021;10(6):7073\u201382.","journal-title":"Ann Palliat Med"},{"key":"700_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215660","volume":"536","author":"C Chen","year":"2022","unstructured":"Chen C, Guo Y, Huang Q, Wang B, Wang W, Niu J, et al. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma. Cancer Lett. 2022;536: 215660.","journal-title":"Cancer Lett"},{"issue":"5","key":"700_CR60","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1111\/ajco.13916","volume":"19","author":"H Li","year":"2023","unstructured":"Li H, Li Y, Song L, Ai Q, Zhang S. Retrospective review of safety and efficacy of anlotinib in advanced osteosarcoma with metastases after failure of standard multimodal therapy. Asia Pac J Clin Oncol. 2023;19(5):e314\u20139.","journal-title":"Asia Pac J Clin Oncol"},{"key":"700_CR61","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x2023e13152","volume":"57","author":"B Zheng","year":"2024","unstructured":"Zheng B, Sun X, Zhang L, Qu G, Ren C, Yan P, et al. Inhibition of anlotinib-induced autophagy attenuates invasion and migration by regulating epithelial-mesenchymal transition and cytoskeletal rearrangement through ATG5 in human osteosarcoma cells. Braz J Med Biol Res. 2024;57: e13152.","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"700_CR62","doi-asserted-by":"publisher","first-page":"619","DOI":"10.4103\/jcrt.JCRT_1253_20","volume":"17","author":"J Wang","year":"2021","unstructured":"Wang J, Li X, Wang F, Shi D, Zhang J. Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: a retrospective case series study. J Cancer Res Ther. 2021;17(3):619\u201324.","journal-title":"J Cancer Res Ther"},{"key":"700_CR63","doi-asserted-by":"publisher","first-page":"153303382096558","DOI":"10.1177\/1533033820965587","volume":"19","author":"W Guo","year":"2020","unstructured":"Guo W, Chen S, Wu Z, Zhuang W, Yang J. Efficacy and safety of transarterial chemoembolization combined with anlotinib for unresectable hepatocellular carcinoma: a retrospective study. Technol Cancer Res Treat. 2020;19:1533033820965587.","journal-title":"Technol Cancer Res Treat"},{"issue":"7","key":"700_CR64","first-page":"619","volume":"28","author":"YM Wang","year":"2020","unstructured":"Wang YM, Meng Y, Shi XN, Fan SR, Song M. Analysis of clinical efficacy, safety and prognosis of anlotinib hydrochloride in the treatment of advanced primary liver cancer. Chin J Hepatol. 2020;28(7):619\u201324.","journal-title":"Chin J Hepatol"},{"issue":"3","key":"700_CR65","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12072-021-10171-0","volume":"15","author":"Y Sun","year":"2021","unstructured":"Sun Y, Zhou A, Zhang W, Jiang Z, Chen B, Zhao J, et al. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). Hep Intl. 2021;15(3):621\u20139.","journal-title":"Hep Intl"},{"key":"700_CR66","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2147\/DDDT.S358092","volume":"16","author":"XQ Chen","year":"2022","unstructured":"Chen XQ, Zhao YX, Zhang CL, Wang XT, Zhang X, Chen X, et al. Effectiveness and safety of anlotinib with or without PD-1 blockades in the treatment of patients with advanced primary hepatocellular carcinoma: a retrospective, real-world study in China. Drug Des Devel Ther. 2022;16:1483\u201393.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"700_CR67","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2478\/raon-2023-0036","volume":"57","author":"M Kang","year":"2023","unstructured":"Kang M, Xue F, Xu S, Shi J, Mo Y. Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study. Radiol Oncol. 2023;57(3):405\u201310.","journal-title":"Radiol Oncol"},{"issue":"4","key":"700_CR68","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1016\/j.bbrc.2018.08.098","volume":"503","author":"C He","year":"2018","unstructured":"He C, Wu T, Hao Y. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway. Biochem Biophys Res Commun. 2018;503(4):3093\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"700_CR69","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.4149\/neo_2020_191125N1212","volume":"67","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Du FC, Fang FQ, Duan ZJ, Lei W, Shi KG. Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib. Neoplasma. 2020;67(6):1384\u201390.","journal-title":"Neoplasma"},{"issue":"10","key":"700_CR70","doi-asserted-by":"publisher","first-page":"e1693","DOI":"10.1002\/onco.13857","volume":"26","author":"Y Chi","year":"2021","unstructured":"Chi Y, Shu Y, Ba Y, Bai Y, Qin B, Wang X, et al. Anlotinib monotherapy for refractory metastatic colorectal cancer: a double-blinded, placebo-controlled, randomized phase III trial (ALTER0703). Oncologist. 2021;26(10):e1693\u2013703.","journal-title":"Oncologist"},{"issue":"1","key":"700_CR71","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12916-022-02357-6","volume":"20","author":"Y Liu","year":"2022","unstructured":"Liu Y, Xiao Q, He J, Hu H, Du J, Zhu Y, et al. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS\/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy. BMC Med. 2022;20(1):155.","journal-title":"BMC Med"},{"key":"700_CR72","doi-asserted-by":"publisher","first-page":"153303382311523","DOI":"10.1177\/15330338231152350","volume":"22","author":"J He","year":"2023","unstructured":"He J, Liu Y, Liu C, Hu H, Sun L, Xu D, et al. A randomized phase III study of anlotinib versus bevacizumab in combination with CAPEOX as first-line therapy for RAS\/BRAF wild-type metastatic colorectal cancer: a clinical trial protocol. Technol Cancer Res Treat. 2023;22:15330338231152350.","journal-title":"Technol Cancer Res Treat"},{"issue":"15","key":"700_CR73","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.2174\/1871520621666210112113852","volume":"21","author":"W Lan","year":"2021","unstructured":"Lan W, Zhao J, Chen W, Shang H, Peng J, Lin J. Anlotinib overcomes multiple drug resistant colorectal cancer cells via inactivating PI3K\/AKT pathway. Anticancer Agents Med Chem. 2021;21(15):1987\u201395.","journal-title":"Anticancer Agents Med Chem"},{"issue":"5","key":"700_CR74","first-page":"2331","volume":"25","author":"ZX Jia","year":"2021","unstructured":"Jia ZX, Zhang Z, Li Z, Li A, Xie YN, Wu HJ, et al. Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR\/JAK2\/STAT3 axis. Eur Rev Med Pharmacol Sci. 2021;25(5):2331\u201343.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"700_CR75","doi-asserted-by":"publisher","first-page":"8965903","DOI":"10.1155\/2022\/8965903","volume":"2022","author":"B Luo","year":"2022","unstructured":"Luo B, Zhang S, Tan D, Yu X, Lin J, Wang M. Anlotinib benefits the \u03b1PDL1 immunotherapy by activating ROS\/JNK\/AP-1 pathway to upregulate PDL1 expression in colorectal cancer. Oxid Med Cell Longev. 2022;2022:8965903.","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"700_CR76","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","volume":"30","author":"HY Small","year":"2014","unstructured":"Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol. 2014;30(5):534\u201343.","journal-title":"Can J Cardiol"},{"issue":"1","key":"700_CR77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40262-015-0302-2","volume":"55","author":"B Wulkersdorfer","year":"2016","unstructured":"Wulkersdorfer B, Zeitlinger M, Schmid M. Pharmacokinetic aspects of vascular endothelial growth factor tyrosine kinase inhibitors. Clin Pharmacokinet. 2016;55(1):47\u201377.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"700_CR78","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2215\/CJN.05610522","volume":"18","author":"A Rashidi","year":"2023","unstructured":"Rashidi A, Wanchoo R, Izzedine H. How I manage hypertension and proteinuria associated with VEGF inhibitor. Clin J Am Soc Nephrol. 2023;18(1):121\u20133.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"700_CR79","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cncr.28972","volume":"121","author":"OP Hamnvik","year":"2015","unstructured":"Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121(2):311\u20139.","journal-title":"Cancer"},{"issue":"7 Suppl 2","key":"700_CR80","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1097\/01.ASN.0000070141.69483.5A","volume":"14","author":"LJ Appel","year":"2003","unstructured":"Appel LJ. Lifestyle modification as a means to prevent and treat high blood pressure. J Am Soc Nephrol. 2003;14(7 Suppl 2):S99-s102.","journal-title":"J Am Soc Nephrol"},{"issue":"740","key":"700_CR81","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.3399\/BJGP.2022.0564","volume":"74","author":"H Greenwood","year":"2024","unstructured":"Greenwood H, Barnes K, Ball L, Glasziou P. Comparing dietary strategies to manage cardiovascular risk in primary care: a narrative review of systematic reviews. Br J Gen Pract. 2024;74(740):e199-207.","journal-title":"Br J Gen Pract"},{"issue":"11","key":"700_CR82","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1001\/jama.279.11.839","volume":"279","author":"PK Whelton","year":"1998","unstructured":"Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, TONE Collaborative Research Group, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998;279(11):839\u201346.","journal-title":"JAMA"},{"issue":"10","key":"700_CR83","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1056\/NEJMra1203528","volume":"369","author":"M Ezzati","year":"2013","unstructured":"Ezzati M, Riboli E. Behavioral and dietary risk factors for noncommunicable diseases. N Engl J Med. 2013;369(10):954\u201364.","journal-title":"N Engl J Med"},{"issue":"10","key":"700_CR84","doi-asserted-by":"publisher","first-page":"687","DOI":"10.7326\/0000605-200911170-00148","volume":"151","author":"HB Bosworth","year":"2009","unstructured":"Bosworth HB, Olsen MK, Grubber JM, Neary AM, Orr MM, Powers BJ, et al. Two self-management interventions to improve hypertension control: a randomized trial. Ann Intern Med. 2009;151(10):687\u201395.","journal-title":"Ann Intern Med"},{"issue":"3","key":"700_CR85","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","volume":"80","author":"JB Cohen","year":"2023","unstructured":"Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM, et al. Cancer therapy-related hypertension: a scientific statement from the American Heart Association. Hypertension. 2023;80(3):e46\u201357.","journal-title":"Hypertension"},{"issue":"2","key":"700_CR86","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol. 2019;30(2):187\u2013200.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"700_CR87","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1097\/TP.0000000000000750","volume":"99","author":"W Cheungpasitporn","year":"2015","unstructured":"Cheungpasitporn W, Chebib FT, Cornell LD, Brodin ML, Nasr SH, Schinstock CA, et al. Intravitreal antivascular endothelial growth factor therapy may induce proteinuria and antibody mediated injury in renal allografts. Transplantation. 2015;99(11):2382\u20136.","journal-title":"Transplantation"},{"issue":"9","key":"700_CR88","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/ndt\/gfu368","volume":"30","author":"M Ollero","year":"2015","unstructured":"Ollero M, Sahali D. Inhibition of the VEGF signalling pathway and glomerular disorders. Nephrol Dial Transplant. 2015;30(9):1449\u201355.","journal-title":"Nephrol Dial Transplant"},{"key":"700_CR89","doi-asserted-by":"publisher","first-page":"1686804","DOI":"10.1155\/2023\/1686804","volume":"2023","author":"D Sun","year":"2023","unstructured":"Sun D, Guo J, Liang W, Chen Y, Chen X, Wang L. Anlotinib alleviates renal fibrosis via inhibition of the ERK and AKT signaling pathways. Oxid Med Cell Longev. 2023;2023:1686804.","journal-title":"Oxid Med Cell Longev"},{"issue":"7","key":"700_CR90","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","volume":"6","author":"C Robert","year":"2005","unstructured":"Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491\u2013500.","journal-title":"Lancet Oncol"},{"issue":"3","key":"700_CR91","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1634\/theoncologist.2008-0237","volume":"14","author":"R Anderson","year":"2009","unstructured":"Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, Lacouture ME. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist. 2009;14(3):291\u2013302.","journal-title":"Oncologist"},{"issue":"3","key":"700_CR92","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","volume":"158","author":"CH Yang","year":"2008","unstructured":"Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158(3):592\u20136.","journal-title":"Br J Dermatol"},{"issue":"1","key":"700_CR93","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1679\/aohc.61.17","volume":"61","author":"L Fan","year":"1998","unstructured":"Fan L, Iseki S. Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. Arch Histol Cytol. 1998;61(1):17\u201328.","journal-title":"Arch Histol Cytol"},{"issue":"5","key":"700_CR94","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ctrv.2010.01.003","volume":"36","author":"M Schmidinger","year":"2010","unstructured":"Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev. 2010;36(5):416\u201324.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"700_CR95","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.bjc.6603990","volume":"97","author":"P Osterlund","year":"2007","unstructured":"Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007;97(8):1028\u201334.","journal-title":"Br J Cancer"},{"issue":"1","key":"700_CR96","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2036.2012.05127.x","volume":"36","author":"E Placidi","year":"2012","unstructured":"Placidi E, Marciani L, Hoad CL, Napolitano A, Garsed KC, Pritchard SE, et al. The effects of loperamide, or loperamide plus simethicone, on the distribution of gut water as assessed by MRI in a mannitol model of secretory diarrhoea. Aliment Pharmacol Ther. 2012;36(1):64\u201373.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"700_CR97","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1023\/A:1008390308416","volume":"10","author":"BH Lenfers","year":"1999","unstructured":"Lenfers BH, Loeffler TM, Droege CM, Hausamen TU. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol. 1999;10(10):1251\u20133.","journal-title":"Ann Oncol"},{"issue":"10","key":"700_CR98","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1007\/BF01300194","volume":"32","author":"MI Dueno","year":"1987","unstructured":"Dueno MI, Bai JC, Santangelo WC, Krejs GJ. Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel. Dig Dis Sci. 1987;32(10):1092\u20136.","journal-title":"Dig Dis Sci"},{"issue":"9","key":"700_CR99","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s10147-021-01959-z","volume":"26","author":"Y Chi","year":"2021","unstructured":"Chi Y, Ji G, Zhang J, Tang H, Yang Y, Liu W, et al. Efficacy and safety of anlotinib in patients with advanced malignancy: a single-center, single-arm, phase 2 trial. Int J Clin Oncol. 2021;26(9):1611\u20138.","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"700_CR100","first-page":"493","volume":"3","author":"A Testa","year":"1996","unstructured":"Testa A, Gebbia V, Borsellino N, Valenza R, Cannata G, Tirrito M, et al. Usefulness of oral medroxyprogesterone acetate in the management of cancer-related cachexia-anorexia syndrome. Oncol Rep. 1996;3(3):493\u20136.","journal-title":"Oncol Rep"},{"issue":"2","key":"700_CR101","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bbi.2006.09.006","volume":"21","author":"R Dantzer","year":"2007","unstructured":"Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun. 2007;21(2):153\u201360.","journal-title":"Brain Behav Immun"},{"issue":"19\u201320","key":"700_CR102","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1111\/jocn.12211","volume":"22","author":"E Patterson","year":"2013","unstructured":"Patterson E, Wan YW, Sidani S. Nonpharmacological nursing interventions for the management of patient fatigue: a literature review. J Clin Nurs. 2013;22(19\u201320):2668\u201378.","journal-title":"J Clin Nurs"},{"issue":"11","key":"700_CR103","first-page":"Cd006145","volume":"11","author":"F Cramp","year":"2012","unstructured":"Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2012;11(11):Cd006145.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9504","key":"700_CR104","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","volume":"367","author":"S Tyring","year":"2006","unstructured":"Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29\u201335.","journal-title":"Lancet"},{"issue":"4","key":"700_CR105","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jpainsymman.2010.06.020","volume":"41","author":"O Minton","year":"2011","unstructured":"Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage. 2011;41(4):761\u20137.","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"700_CR106","doi-asserted-by":"publisher","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","volume":"290","author":"T Kamba","year":"2006","unstructured":"Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290(2):H560\u201376.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"9","key":"700_CR107","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1210\/jc.2007-0586","volume":"92","author":"D Mannavola","year":"2007","unstructured":"Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92(9):3531\u20134.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"700_CR108","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/thy.2006.0308","volume":"17","author":"E Wong","year":"2007","unstructured":"Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17(4):351\u20135.","journal-title":"Thyroid"},{"issue":"6","key":"700_CR109","doi-asserted-by":"publisher","first-page":"988","DOI":"10.4158\/EP12280.GL","volume":"18","author":"JR Garber","year":"2012","unstructured":"Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988\u20131028.","journal-title":"Endocr Pract"},{"issue":"1","key":"700_CR110","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/jnci\/djk008","volume":"99","author":"BI Rini","year":"2007","unstructured":"Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99(1):81\u20133.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"700_CR111","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1089\/thy.2013.0398","volume":"24","author":"CS Fuziwara","year":"2014","unstructured":"Fuziwara CS, Kimura ET. High iodine blocks a Notch\/miR-19 loop activated by the BRAF(V600E) oncoprotein and restores the response to TGF\u03b2 in thyroid follicular cells. Thyroid. 2014;24(3):453\u201362.","journal-title":"Thyroid"},{"issue":"6","key":"700_CR112","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.3324\/haematol.2022.280884","volume":"108","author":"W Zhang","year":"2023","unstructured":"Zhang W, Yu G, Zhang H, Basyal M, Ly C, Yuan B, et al. Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy. Haematologica. 2023;108(6):1500\u201314.","journal-title":"Haematologica"},{"issue":"6","key":"700_CR113","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1182\/blood.2022018196","volume":"142","author":"S Qiu","year":"2023","unstructured":"Qiu S, Sheth V, Yan C, Liu J, Chacko BK, Li H, et al. Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells. Blood. 2023;142(6):574\u201388.","journal-title":"Blood"},{"issue":"22","key":"700_CR114","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075\u201388.","journal-title":"N Engl J Med"},{"issue":"10","key":"700_CR115","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327.","journal-title":"N Engl J Med"},{"key":"700_CR116","doi-asserted-by":"publisher","first-page":"1393404","DOI":"10.3389\/fimmu.2024.1393404","volume":"15","author":"C Zhou","year":"2024","unstructured":"Zhou C, Wang W, Mu Y, Meng M. Efficacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms: a systematic review and meta-analysis. Front Immunol. 2024;15:1393404.","journal-title":"Front Immunol"},{"issue":"3","key":"700_CR117","doi-asserted-by":"publisher","first-page":"753","DOI":"10.20892\/j.issn.2095-3941.2020.0024","volume":"17","author":"T Qin","year":"2020","unstructured":"Qin T, Liu Z, Wang J, Xia J, Liu S, Jia Y, et al. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling. Cancer Biol Med. 2020;17(3):753\u201367.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"700_CR118","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-019-0731-8","volume":"12","author":"C Zhang","year":"2019","unstructured":"Zhang C, Leighl NB, Wu Y-L, Zhong W-Z. Emerging therapies for non-small cell lung cancer. J Hematol Oncol. 2019;12(1):45.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"700_CR119","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1007\/s12325-021-01889-2","volume":"38","author":"J Gong","year":"2021","unstructured":"Gong J, Wan Q, Shang J, Qian X, Su D, Sun Z, et al. Cost-effectiveness analysis of anlotinib as third- or further-line treatment for relapsed small cell lung cancer (SCLC) in China. Adv Ther. 2021;38(10):5116\u201326.","journal-title":"Adv Ther"},{"key":"700_CR120","doi-asserted-by":"publisher","first-page":"1122294","DOI":"10.3389\/fonc.2023.1122294","volume":"13","author":"J-Y Huang","year":"2023","unstructured":"Huang J-Y, Xie X-F, Chen X-L, Zhang Q-Y, Chen L-P, Bai X, et al. A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer. Front Oncol. 2023;13:1122294.","journal-title":"Front Oncol"},{"key":"700_CR121","doi-asserted-by":"publisher","first-page":"102543","DOI":"10.1016\/j.eclinm.2024.102543","volume":"70","author":"S Ma","year":"2024","unstructured":"Ma S, He Z, Liu Y, Wang L, Yang S, Wu Y, et al. Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial. eClinicalMedicine. 2024;70:102543.","journal-title":"eClinicalMedicine"},{"issue":"4","key":"700_CR122","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/ijc.34546","volume":"153","author":"B-D Qin","year":"2023","unstructured":"Qin B-D, Jiao X-D, Wang Z, Liu K, Wu Y, Ling Y, et al. Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: a single-arm, open-label, phase II trial. Int J Cancer. 2023;153(4):815\u201325.","journal-title":"Int J Cancer"},{"issue":"4","key":"700_CR123","doi-asserted-by":"publisher","first-page":"399","DOI":"10.21147\/j.issn.1000-9604.2023.04.06","volume":"35","author":"J Wang","year":"2023","unstructured":"Wang J, Xiang X, Shi Z, Zhang H, Zhang Q, Liu Z, et al. Efficacy and safety of anlotinib as an adjuvant therapy in hepatocellular carcinoma patients with a high risk of postoperative recurrence. Chin J Cancer Res. 2023;35(4):399\u2013407.","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"700_CR124","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12916-023-03140-x","volume":"21","author":"Y Fang","year":"2023","unstructured":"Fang Y, Su N, Zou Q, Cao Y, Xia Y, Tang L, et al. Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial. BMC Med. 2023;21(1):423.","journal-title":"BMC Med"},{"key":"700_CR125","doi-asserted-by":"publisher","first-page":"1059995","DOI":"10.3389\/fimmu.2022.1059995","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen S, Wei H, Zhao W, Jiang W, Ning R, Zhou S, et al. PD-1\/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1\/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: a real-world retrospective cohort study. Front Immunol. 2022;13:1059995.","journal-title":"Front Immunol"},{"issue":"5","key":"700_CR126","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.21037\/tlcr-23-260","volume":"12","author":"L Yu","year":"2023","unstructured":"Yu L, Xu J, Qiao R, Zhong H, Brueckl WM, Zhong R. Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study. Transl Lung Cancer Res. 2023;12(5):1108\u201321.","journal-title":"Transl Lung Cancer Res"},{"issue":"8","key":"700_CR127","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1738","volume":"14","author":"F Song","year":"2024","unstructured":"Song F, Hu B, Liang X-L, Cheng J-W, Wang C-G, Wang P-X, et al. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8+ T-cell infiltration in hepatocellular carcinoma. Clin Transl Med. 2024;14(8): e1738.","journal-title":"Clin Transl Med"},{"issue":"3","key":"700_CR128","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ijc.34536","volume":"153","author":"L Yu","year":"2023","unstructured":"Yu L, Hu Y, Xu J, Qiao R, Zhong H, Han B, et al. Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy. Int J Cancer. 2023;153(3):635\u201343.","journal-title":"Int J Cancer"},{"key":"700_CR129","doi-asserted-by":"publisher","first-page":"6329","DOI":"10.2147\/IJN.S321720","volume":"16","author":"G Gu","year":"2021","unstructured":"Gu G, Hu C, Hui K, Zhang H, Chen T, Zhang X, et al. Exosomal miR-136\u20135p derived from anlotinib-resistant NSCLC cells confers anlotinib resistance in non-small cell lung cancer through targeting PPP2R2A. Int J Nanomed. 2021;16:6329\u201343.","journal-title":"Int J Nanomed"},{"issue":"8","key":"700_CR130","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/CAD.0000000000001626","volume":"35","author":"B Liu","year":"2024","unstructured":"Liu B, Peng Y, Su Y, Diao C, Qian J, Zhan X, et al. Transcriptome and metabolome sequencing identifies glutamate and LPAR1 as potential factors of anlotinib resistance in thyroid cancer. Anticancer Drugs. 2024;35(8):741\u201351.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"700_CR131","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12967-022-03451-2","volume":"20","author":"S Wang","year":"2022","unstructured":"Wang S, Lou N, Luo R, Hao X, Liu Y, Wang L, et al. Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC. J Transl Med. 2022;20(1):248.","journal-title":"J Transl Med"},{"issue":"1","key":"700_CR132","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12935-023-03164-6","volume":"23","author":"Z Liu","year":"2023","unstructured":"Liu Z, Wang X, Li C, Zhao R. The function and mechanism of PSMD14 in promoting progression and resistance to anlotinib in osteosarcoma. Cancer Cell Int. 2023;23(1):309.","journal-title":"Cancer Cell Int"},{"key":"700_CR133","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.2147\/CMAR.S364125","volume":"14","author":"H-R Zheng","year":"2022","unstructured":"Zheng H-R, Jiang A-M, Gao H, Liu N, Zheng X-Q, Fu X, et al. The efficacy and safety of anlotinib in extensive-stage small cell lung cancer: a multicenter real-world study. Cancer Manage Res. 2022;14:2273\u201387.","journal-title":"Cancer Manage Res"},{"key":"700_CR134","doi-asserted-by":"publisher","first-page":"117955492110671","DOI":"10.1177\/11795549211067184","volume":"16","author":"Y Li","year":"2022","unstructured":"Li Y, Sun Z, Sun W, Wang H, Zu J. Effectiveness and safety of anlotinib monotherapy for patients with extensive-stage small-cell lung cancer who progressed to chemotherapy: a real-world exploratory study. Clin Med Insights Oncol. 2022;16:11795549211067184.","journal-title":"Clin Med Insights Oncol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00700-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00700-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00700-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T12:57:45Z","timestamp":1742216265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00700-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":134,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00700-1","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"3 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}